On October 28, Novartis released its 2025 Q3 financial report, showing strong performance in the first nine months.Net sales reachedUSD 41.196 billion, an increase of 11% year-on-year(At fixed exchange rates), Core Operating Revenue$16.96 billion, up 18%;Among which, the third quarterNet sales were $13.909 billion, an increase of 7% year-on-year,Net profit was US$3.93 billion, a year-on-year increase of 25%.Source: Novartis Financial Report, same as belowNovartis focuses onCardiovascular-Renal-Metabolism, Immunology, Neuroscience, and OncologyFour Major Disease Areas. The sales growth in the third quarter was mainly driven by the continued strong performance of some products, includingKisqali (Ribociclib, +68%),Kesimpta(Ofatumumab, +44%),Pluvicto（+45%）、Scemblix(Asciminib, +95%).In the first nine months of 2025, Novartis was the most popularThe drug sold isEntresto、Cosentyx andKisqali, respectively achieved$64.95 billion, $48.61 billion, and $34.62 billionSales.Star Nuclear MedicinePluvicto Sales Reach $1.389 Billion in the First Nine MonthsSince its launch in 2022, the product has maintained rapid growth and surpassed 1 billion U.S. dollars for the first time in 2024. Another nuclear medicine, Lutathera, generated 613 million U.S. dollars in revenue in the first nine months, representing a year-on-year increase of 14%.Q4 2025,Novartis Pluvicto is expected to be approved for marketing in China.At the same time, Novartis reaffirmed its full-year 2025 guidance, expecting high single-digit sales growth and core operating income to grow by more than ten percent.
Cover Source:Corporate logo
Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.
Editor: ccai
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn
